Leal Therapeutics Secures $30 Million in Latest Pre-Seed Funding Round

Leal Therapeutics secured $30 million in its latest Pre-Seed, adding another data point to the Healthcare & Life Sciences funding market.

Leal Therapeutics Raises $30 million in Funding

Leal Therapeutics Raises $30M in Second Close of Series A Funding. “We’re grateful to our new and existing investors for their shared commitment to advancing this work.” [.] LTX-002, a near-clinical stage antisense oligonucleotide (ASO), is in development for genetic and sporadic ALS.

Investors Behind the Funding

The round was backed by SV Health Investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Leal Therapeutics operates in Healthcare & Life Sciences. Leal Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Advance its neuro-metabolic therapies for CNS disorders.

Looking Ahead

Leal Therapeutics Raises $30M in Second Close of Series A Funding

Source reference: original announcement/article.